Ovarian cancer relapse: From the latest scientific evidence to the best practice-Reference-Cited by-同舟云学术

Ovarian cancer relapse: From the latest scientific evidence to the best practice

Published:2019-08 Issue: Volume:140 Page:28-38
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Luvero Daniela,Plotti Francesco,Aloisia Alessia,Montera Roberto,Terranova Corrado,Carlo De Cicco Nardone ,Scaletta Giuseppe,Lopez Salvatore,Miranda Andrea^ORCID,Capriglione Stella,Gatti Alessandra,Pierluigi Benedetti Panici ,Angioli Roberto

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference93 articles.

1. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential;Luvero;Ther. Adv. Med. Oncol.,2014

2. Optimizing treatment of the partially platinum sensitive ovarian cancer patient;Colombo;Future Oncol.,2013

3. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin;Markman;J. Clin. Oncol.,1991

4. Management of partially platinum-sensitive relapsed ovarian cancer;Kaye;Eur. J. Cancer,2008

5. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds;Gore;Gynecol. Oncol.,1990

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of prevention marker associated with DNA replication in ovarian cancer: Expression of MCM2 protein and bioinformatics analysis;International Journal of Biological Macromolecules;2024-11

2. Cationic liposomes overcome neutralizing antibodies and enhance reovirus efficacy in ovarian cancer;Virology;2024-10

3. Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis;Taiwanese Journal of Obstetrics and Gynecology;2024-09

4. Prescribers and patients drive maintenance therapy patterns in a community oncology practice: National guidelines versus the real-world experience;Gynecologic Oncology Reports;2024-08

5. NK cell line modified to express a potent, DR5 specific variant of TRAIL, show enhanced cytotoxicity in ovarian cancer models;Heliyon;2024-08